617 related articles for article (PubMed ID: 33738702)
41. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
42. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
[TBL] [Abstract][Full Text] [Related]
43. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
44. Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.
Bozzoli V; Tisi MC; Maiolo E; Alma E; Bellesi S; D'Alo' F; Voso MT; Leone G; Hohaus S
Br J Haematol; 2015 Jun; 169(6):787-94. PubMed ID: 25819007
[TBL] [Abstract][Full Text] [Related]
45. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Pettengell R; Johnsen HE; Lugtenburg PJ; Silvestre AS; Dührsen U; Rossi FG; Schwenkglenks M; Bendall K; Szabo Z; Jaeger U
Support Care Cancer; 2012 Mar; 20(3):647-52. PubMed ID: 22101611
[TBL] [Abstract][Full Text] [Related]
46. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
[TBL] [Abstract][Full Text] [Related]
47. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
48. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma.
Mey UJ; Maier A; Schmidt-Wolf IG; Ziske C; Forstbauer H; Banat GA; Reber M; Strehl JW; Gorschlueter M
Support Care Cancer; 2007 Jul; 15(7):877-84. PubMed ID: 17235504
[TBL] [Abstract][Full Text] [Related]
49. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma.
Gao Y; Xie Y; Liu L; Xue H; Hou M; Zhang M; Zhou Z; Guo P; Yao H; Shao Z; Xie X; Zhu J
Minerva Med; 2021 Apr; 112(2):310-312. PubMed ID: 31317691
[No Abstract] [Full Text] [Related]
51. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
[TBL] [Abstract][Full Text] [Related]
52. Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: A nation-wide analysis in Japan.
Matsuda K; Jo T; Miyauchi M; Toyama K; Nakazaki K; Matsui H; Fushimi K; Yasunaga H; Kurokawa M
J Infect Chemother; 2021 Aug; 27(8):1151-1155. PubMed ID: 33745811
[TBL] [Abstract][Full Text] [Related]
53. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy.
Donnelly GB; Glassman J; Long C; Torres P; Straus DJ; O'Brien JP; Bertino J; Moskowitz CH; Zelenetz AD; Portlock CS
Leuk Lymphoma; 2000 Sep; 39(1-2):67-75. PubMed ID: 10975385
[TBL] [Abstract][Full Text] [Related]
54. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
55. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
[TBL] [Abstract][Full Text] [Related]
56. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
[TBL] [Abstract][Full Text] [Related]
57. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
[TBL] [Abstract][Full Text] [Related]
58. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
[TBL] [Abstract][Full Text] [Related]
59. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
[No Abstract] [Full Text] [Related]
60. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY
Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
